Public Sector Pension Investment Board Has $16.96 Million Stock Holdings in Bristol Myers Squibb Company (NYSE:BMY)

Key Points

• The Public Sector Pension Investment Board increased its stake in Bristol Myers Squibb by 8.7%, holding 278,093 shares valued at $16.96 million as of the last reporting period.
• Bristol Myers Squibb reported a quarterly EPS of $1.46, significantly surpassing analyst estimates of $1.07, with a revenue of $12.27 billion, up 0.6% year-over-year.
• The company announced a quarterly dividend of $0.62 per share, reflecting a dividend yield of 5.4%, with a payout ratio of 100%.

Public Sector Pension Investment Board increased its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 8.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 278,093 shares of the biopharmaceutical company's stock after buying an additional 22,229 shares during the period. Public Sector Pension Investment Board's holdings in Bristol Myers Squibb were worth $16,961,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in BMY. Pinney & Scofield Inc. bought a new position in Bristol Myers Squibb in the 4th quarter valued at about $25,000. Park Square Financial Group LLC bought a new position in Bristol Myers Squibb in the 4th quarter valued at about $26,000. Transce3nd LLC bought a new position in shares of Bristol Myers Squibb during the 4th quarter worth approximately $28,000. Global Wealth Strategies & Associates lifted its position in shares of Bristol Myers Squibb by 137.5% during the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 275 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. bought a new position in shares of Bristol Myers Squibb during the 1st quarter worth approximately $31,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Stock Down 0.1%

BMY opened at $45.91 on Tuesday. The company has a fifty day moving average price of $47.26 and a 200-day moving average price of $51.72. The firm has a market capitalization of $93.45 billion, a P/E ratio of 18.51, a price-to-earnings-growth ratio of 2.35 and a beta of 0.36. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11. Bristol Myers Squibb Company has a one year low of $42.96 and a one year high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, beating analysts' consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The firm had revenue of $12.27 billion during the quarter, compared to analyst estimates of $11.32 billion. During the same period in the previous year, the business earned $2.07 EPS. The business's revenue for the quarter was up .6% on a year-over-year basis. Equities research analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd were issued a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.4%. The ex-dividend date of this dividend was Thursday, July 3rd. Bristol Myers Squibb's payout ratio is currently 100.00%.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Morgan Stanley reissued a "hold" rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Piper Sandler assumed coverage on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 target price on the stock. Cantor Fitzgerald reissued a "neutral" rating and set a $55.00 target price on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. Daiwa Capital Markets cut shares of Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 target price on the stock. in a research report on Tuesday, August 5th. Finally, Argus raised shares of Bristol Myers Squibb to a "hold" rating in a report on Friday, April 25th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $56.38.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.